Events

Avis De Sécurité sur WATCHMAN FLX™ Left Atrial Appendage (LAA) Closure Device

Selon Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (via FOI), ce/cet/cette avis de sécurité concerne un dispositif en/au/aux/à Slovenia qui a été fabriqué par Boston Scientific International S.A..

Qu'est-ce que c'est?

Les avis de sécurité sont des communications que les fabricants de dispositifs médicaux ou leurs représentants font parvenir en particulier aux travailleurs du secteur médical, mais aussi aux utilisateurs de ces dispositifs. Les avis de sécurité concernent les actions entreprises quant aux dispositifs présents sur le marché et peuvent inclure des rappels et des alertes.

En savoir plus sur les données ici
  • Type d'événement
    Field Safety Notice
  • Pays de l'événement
    Slovenia
  • Source de l'événement
    AMPMDRS
  • Notes / Alertes
    Data from Slovenia is current through February 2019. All of the data comes from the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (via FOI), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Slovenia.
  • Notes supplémentaires dans les données
  • Cause
    Boston scientific is implementing a voluntary medical device removal of all non-implanted watchman flx™ left atrial appendage closure (laac) devices. the reason for this action is that boston scientific has received an increased number (6 of 207 – 2.9%) of implant embolization reports both during procedure (2) and post procedure (4) on the watchman flx laac devices. each embolized flx device was successfully retrieved percutaneously without permanent embolization. note: one patient died due to complications related to a post-operative infection after percutaneous removal of their flx device. .

Device

WATCHMAN FLX™ Left Atrial Appendage (LAA) Closure Device
  • Modèle / numéro de série
    WS5020 18225672, 18225673, 18225674, 18396812, 18401612, 18459184, 18581834, 18603231, 18682283, 18688431, 18688432, 18707084, 18736313, 18751534, 18751536, 18838165, 18845130, 18875658, 18900177, 18914801, 18914802, 18929298 WS5024 18396813, 18401613, 18408201, 18408202, 18435076, 18480472, 18492730, 18581835, 18591486, 18603232, 18682284, 18682288, 18688428, 18707085, 18736314, 18742868, 18751537, 18838166, 18866426, 18900176, 18914803, 18915361, 18934783, 18944586, 18972521, 18979870 WS5027 18396814, 18408203, 18409435, 18435077, 18459185, 18492731, 18581836, 18591490, 18682285, 18682289, 18707086, 18736315, 18751538, 18751539, 18838167, 18866427, 18876065, 18908883, 18914808, 18914809, 18914810, 18914811, 18914812, 18929299, 18934786, 18944584, 18944587, 18972522, 18979879, 18989184 WS5031 18396811, 18408205, 18435078, 18459186, 18534734, 18581837, 18591358, 18682286, 18707087, 18736316, 18752110, 18832856, 18845134, 18876063, 18893436, 18914813, 18934784, 18944588, 18980043, 18989186 WS5035 18182797, 18225668, 18225671, 18401059, 18435079, 18483583, 18581838, 18682287, 18707088, 18736317, 18751760, 18832857, 18845135, 18876066, 18900178, 18914814, 18934785
  • Manufacturer
    Boston Scientific International S.A.

Manufacturer

Boston Scientific International S.A.
  • Société-mère du fabricant (2017)
    Boston Scientific
  • Commentaire du fabricant
    “We take a patient-first approach to assessing the applicability of every recall and communicate to regulatory bodies in all geographies where the recalled device is sold,” Boston Scientific said in a statement to ICIJ. “We have coordinated several recalls across many countries in a timely manner,” the company said, adding that it complies with all national laws, which can often vary and require different processes for reporting information or taking action on recalls. The company said it uses a rigorous and uniform process to take action on recalls and that “when we initiate a field action (e.g. recall, safety alert), every customer who has received an affected product receives a communication that includes a letter for the physician.”
  • Source
    AMPMDRS